The Role of B-Type Natriuretic Peptide Testing in the Diagnosis and Prognosis of Acute Heart Failure: A Review of Foundational Evidence

Abstract

Introduction: The clinical assessment of patients presenting with acute dyspnea is a frequent and often complex challenge, with the differentiation of acute decompensated heart failure (ADHF) from other etiologies being critical. The cardiac neurohormones B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), which are released in response to myocardial stress, were investigated as potential biomarkers to aid in this dilemma.

Literature Review: A review of the pivotal scientific literature reveals the transformative impact of natriuretic peptide testing on the management of heart failure. A landmark, large-scale, multinational prospective study definitively established that measuring plasma BNP levels significantly improved the accuracy of diagnosing ADHF in the emergency department setting. Subsequent large studies confirmed these findings for NT-proBNP. Beyond their diagnostic utility, a substantial body of evidence from numerous cohort studies demonstrated that natriuretic peptide levels are powerful and independent predictors of adverse outcomes. Elevated admission and discharge levels of BNP or NT-proBNP were consistently shown to be strongly associated with increased short- and long-term risk of mortality and rehospitalization. This robust evidence base led to the rapid integration of natriuretic peptide testing into major international clinical practice guidelines.

Conclusion: The body of work reviewed confirms that natriuretic peptide measurement is an essential tool in the evaluation of patients with suspected ADHF. It provides rapid, objective information that enhances diagnostic accuracy, offers powerful prognostic insights, and has become a standard of care in modern cardiovascular medicine.